EURX Eurand N.V. (MM)

MILAN, Italy and DAYTON, Ohio, Aug. 23 /PRNewswire-FirstCall/ -- Eurand N.V. (NASDAQ:EURX), announced today that Cephalon, Inc. (NASDAQ:CEPH) has signed an agreement to acquire Amrix(R) from ECR Pharmaceuticals ("ECR"). Amrix(R) is an extended release muscle relaxant product developed by Eurand for ECR using its proprietary Diffucaps(R) technology. Eurand, as the licensor and exclusive manufacturer of the product, will now work with Cephalon to support the commercialization of the product in the United States. Eurand will receive royalty payments from Cephalon on Amrix(R) sales. ECR received approval of Amrix(R) from the U.S. Food and Drug Administration (FDA) in February 2007. Amrix(R) is indicated for short-term use as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Gearoid Faherty, Chief Executive Officer of Eurand, said, "We would like to recognize the efforts of our partner, ECR, in obtaining regulatory approval for Amrix(R) and look forward to working with Cephalon in commercialization of the product in the United States." About Eurand Eurand is a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Eurand has had four products approved by the FDA since 2000 and has a pipeline of product candidates in development for itself and its collaboration partners. Eurand has completed two phase III clinical trials on its lead product candidate Zentase(TM) for the treatment of Exocrine Pancreatic Insufficiency and filed an NDA for this product in June 2007. Eurand's technology platforms include bioavailability enhancement of poorly soluble drugs, customized release, taste-making/fast-dissolving formulations and drug conjugation. Eurand is a global company with facilities in the USA and Europe. For more information, visit Eurand's website at http://www.eurand.com/. Certain statements made in this release, and oral statements made with respect to information contained in this release, may constitute forward- looking statements. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. The words "potentially", "could", "expects" and similar expressions will some times identify forward-looking statements. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Forward- looking statements contained in this press release are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Actual events could differ materially from those anticipated in the forward- looking statements. CONTACTS: Marian Cutler Nick Laudico / Elizabeth Scott Vice President, The Ruth Group Corporate Communications 646-536-7030 / 7014 Eurand 973-517-0519 DATASOURCE: Eurand CONTACT: Marian Cutler, Vice President, Corporate Communications, of Eurand, +1-973-517-0519, ; or Nick Laudico, +1-646-536-7030, , or Elizabeth Scott, +1-646-536-7014, , both of The Ruth Group, for Eurand Web site: http://www.eurand.com/

Copyright